AI-generated research brief — verify at source
Prophylactic Dexamethasone Mouthwash Reduces Severity and Delays Peak Radiation Mucositis
In a randomized placebo-controlled trial, patients using prophylactic dexamethasone mouthwash experienced significantly lower oral mucositis severity at every measured time point (p < 0.01) and roughly half the rate of persistent dysphagia at two months compared with placebo (32% vs 72%, p = 0.01). These results suggest meaningful clinical benefit, though the phase II scale of the study means confirmation in larger trials is necessary before conclusions can be generalized.
What Was Studied
The trial investigated whether a topical dexamethasone oral solution (0.5 mg/10 mL), used as a prophylactic mouthwash throughout radiotherapy, could reduce the incidence and maximum severity of radiation-induced oral mucositis in head and neck cancer patients. This complication is both common and functionally disabling in patients receiving curative-intent high-dose radiotherapy, and effective pharmacological prevention strategies remain limited.
How It Was Studied
This was a randomized, triple-blind, placebo-controlled, parallel-group phase II trial conducted in patients with non-metastatic head and neck squamous cell carcinoma scheduled to receive at least 60 Gy of radiotherapy. Fifty-four patients were allocated 1:1 to either dexamethasone mouthwash or placebo, with instructions to gargle 10 mL four times daily throughout the radiotherapy course. Fifty patients completed the study, with 25 in each arm. Mucositis severity was graded using both the WHO Oral Toxicity Scale and NCI-CTCAE criteria version 5, and secondary assessments included patient-reported pain via visual analogue scale (VAS), dysphagia, treatment discontinuation rates, and mucositis status at a two-month follow-up visit.
What Was Observed
- Mucositis severity was consistently lower across all assessed time points in the dexamethasone arm compared with placebo, as measured by both the WHO and CTCAE grading systems (p < 0.01 at all time points). No grade 4 mucositis events occurred in the dexamethasone group, while two grade 4 events were recorded in the placebo group, indicating a clinically meaningful reduction in the most severe presentations.
- Peak mucositis onset was delayed by approximately two weeks in patients receiving dexamethasone, with maximum severity occurring at week 5 compared with week 3 in the placebo group. This delay may provide a meaningful window during which patients can better tolerate treatment.
- Patient-reported pain scores were substantially lower in the dexamethasone group during weeks 4 through 7, with median VAS scores of 0–3 versus 4–6 in the placebo arm (p < 0.01). This difference corresponds to the period when mucositis typically reaches its worst and most symptomatic phase.
- Dysphagia at two months was more than halved in patients receiving dexamethasone compared with placebo (32% vs 72%, p = 0.01), suggesting a potential benefit that extends beyond the active treatment period. The intervention was well tolerated, with no observed signal of systemic steroid toxicity or increased oral infection rates.
Why This Matters
Radiation-induced oral mucositis is a major source of morbidity during curative radiotherapy for head and neck cancer, contributing to pain, impaired nutrition, and potential treatment interruption. This trial provides preliminary evidence that a low-cost, topically applied corticosteroid given prophylactically may reduce the burden of this complication both during and after radiotherapy. The authors identify this as a rationale for advancing to larger confirmatory multicenter trials with validated patient-reported outcome instruments and direct comparison against currently recommended preventive strategies.
How to Read This Result
While the consistently positive findings across multiple endpoints are encouraging, the study’s small sample size, single-center design, short follow-up horizon, and absence of formal validated outcome instruments place these results firmly in the hypothesis-generating category, warranting cautious interpretation pending replication in adequately powered multicenter trials.
Limitations
The study enrolled only 50 evaluable patients at a single center, limiting statistical power and generalizability. Follow-up extended only to two months post-treatment, leaving the durability of observed benefits uncertain. Patient-reported outcomes were captured using VAS rather than validated head and neck-specific instruments such as the EORTC QLQ-H&N35 or OMAS. No direct comparison was made with guideline-recommended preventive approaches such as photobiomodulation. The investigators acknowledge that larger multicenter trials with longer follow-up are required to confirm these findings.